ANNAPOLIS, Md., Aug. 10 (UPI) -- The U.S. Defense Department is speeding up funding for development of a pre- and post-exposure treatment against nerve agents.
The funding, the result of exercising a contract option, is for PharmAthene Inc.'s rBChE nerve agent medical countermeasure program but is contingent on "the achievement of key milestone activities."
PharmAthene, a bio-defense company, said rBChE is a recombinant form of human butyrylcholinesterase, a natural protein found in minute quantities in blood and which acts like a sponge to absorb toxins such as nerve agents and certain pesticides before irreversible neurological damage.
Read more: http://www.upi.com/Business_News/Security-Industry/2012/08/10/US-funds-nerve-agent-counter-measure/UPI-73071344609796/#ixzz23L8foQtn
Makes one wonder if they are expecting something?
Home